Coronary Syndrome
📧 Sign up to get email alerts when something new happens for Coronary Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2024-09-25Clinical Trial Update: Rehabilitation Exercise with MObile Technology and Education After Acute Coronary Syndrome [NA]
A clinical trial evaluating rehabilitation exercise with mobile technology and education after acute coronary syndrome has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-08-23Clinical Trial Update: Metabolic Substrate of Patients With Myocardial Infarction With and Without Modifiable Cardiovascular Risk Factors
A clinical trial evaluating metabolic substrates in patients with acute myocardial infarction, comparing those with and without modifiable c…
-
CLINICAL_TRIALS withdrawal · 2024-08-22Clinical Trial Update: Use of ARIA in Risk Stratification for Chest Pain Patients Presenting to Emergency Departments Suspected Acute Coronary Syndrome
A clinical trial evaluating the ARIA tool for risk stratification in chest pain patients suspected of acute coronary syndrome was terminated…
-
EMA withdrawal · 2021-01-25EMA Withdrawn: Clopidogrel ratiopharm GmbH (clopidogrel) — Archie Samiel s.r.o.
EMA withdrew clopidogrel from Archie Samiel s.r.o.'s product line, with therapeutic areas including peripheral vascular diseases, acute coro…
-
EMA withdrawal · 2019-05-07EMA Application withdrawn: Canakinumab Novartis (Canakinumab) — Novartis Europharm Limited
The EMA has withdrawn the application for canakinumab by Novartis Europharm Limited for indications in acute coronary syndrome, myocardial i…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2018-09-14EMA Withdrawn: Angiox (Bivalirudin) — The Medicines Company UK Ltd
Angiox (bivalirudin) has been withdrawn from the market in the EU.
-
CLINICAL_TRIALS withdrawal · 2018-04-04Clinical Trial Update: Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis [Phase 4]
A Phase 4 trial comparing the pharmacodynamics of ticagrelor and clopidogrel after thrombolysis in patients with acute coronary syndromes wa…
-
CLINICAL_TRIALS withdrawal · 2018-03-13Clinical Trial Update: Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention [Phase 3]
Phase 3 trial of Aggrastat (tirofiban) in patients undergoing percutaneous coronary intervention for myocardial infarction or acute coronary…
-
EMA withdrawal · 2018-01-04EMA Withdrawn: Clopidogrel Acino (clopidogrel) — Acino AG
Clopidogrel Acino has been withdrawn from the European market.
-
CLINICAL_TRIALS withdrawal · 2017-08-29Clinical Trial Update: Integrated Smoking Cessation and Mood Management for ACS Patients [NA]
The clinical trial investigating integrated smoking cessation and mood management for acute coronary syndrome patients has been withdrawn.
-
EMA withdrawal · 2017-04-28EMA Withdrawn: Clopidogrel/Acetylsalicylic acid Teva (clopidogrel;acetylsalicylic acid) — Teva Pharma B.V.
The EMA withdrew Teva's clopidogrel/acetylsalicylic acid combination product from the market.
-
CLINICAL_TRIALS withdrawal · 2016-12-20Clinical Trial Update: Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During PCI: an OCT Study [Phase 4]
Phase 4 trial comparing ticagrelor versus clopidogrel for residual thrombus burden during PCI (OCT study) has been withdrawn. The study targ…
-
CLINICAL_TRIALS withdrawal · 2016-09-16Clinical Trial Update: Acute Coronary Syndrome Sri Lanka Audit Project
The Sri Lanka acute coronary syndrome audit trial sponsored by the University of Colombo has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-09-28Clinical Trial Update: Factors Contributing To Cardiovascular Morbidity and Mortality in Patients With Gastrointestinal Bleeding
A clinical trial investigating factors contributing to cardiovascular morbidity and mortality in patients with gastrointestinal bleeding. Th…
-
CLINICAL_TRIALS withdrawal · 2015-07-21Clinical Trial Update: Rapid Assessment of Cardiac Markers for the Evaluation of Acute Coronary Syndrome (RACE-ACS) [Phase 4]
The Phase 4 RACE-ACS trial evaluating rapid assessment of cardiac markers for Acute Coronary Syndrome has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-07-21Clinical Trial Update: Evaluation of Serial Troponin and Cardiac Multimarkers at the Point of Care in the Emergency Department
A clinical trial evaluating serial troponin and cardiac multimarkers at the point of care in the emergency department has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-05-12Clinical Trial Update: Pre-discharge vs. Early Post-discharge Stress Testing and GRACE Score for Safe Discharge of ACS-patients With a Negative Hs-troponin T Result
The clinical trial evaluating pre-discharge versus early post-discharge stress testing and GRACE scoring for safe discharge of acute coronar…
-
EMA withdrawal · 2015-02-03EMA Withdrawn: Clopidogrel Teva Pharma B.V. (clopidogrel (as hydrobromide)) — Teva Pharma B.V.
The EMA withdrew clopidogrel Teva Pharma B.V. (clopidogrel as hydrobromide) from marketing.
-
CLINICAL_TRIALS withdrawal · 2014-05-26Clinical Trial Update: Effect of Pretreatment With Ticagrelor on Residual Thrombus After PCI in Patients Presenting With ACS in Comparison With Delayed Treatment at the Time of PCI: an OCT Study [Phase 4]
A Phase 4 trial evaluating pretreatment with ticagrelor to reduce residual thrombus after PCI in patients with acute coronary syndrome has b…
-
EMA withdrawal · 2014-05-12EMA Lapsed: Clopidogrel Teva Generics B.V. (clopidogrel (as hydrochloride)) — Teva Pharma B.V.
EMA has lapsed the marketing authorization for Clopidogrel Teva Generics B.V. (clopidogrel as hydrochloride).
-
CLINICAL_TRIALS withdrawal · 2013-07-31Clinical Trial Update: Efficacy of Preoperative Electrocardiography
The trial evaluating preoperative electrocardiography has been withdrawn.
-
EMA withdrawal · 2013-04-22EMA Withdrawn: Possia (ticagrelor) — AstraZeneca AB
Possia (ticagrelor) has been withdrawn from market authorization by AstraZeneca AB.
-
CLINICAL_TRIALS withdrawal · 2012-10-03Clinical Trial Update: Sicilian Administrative Data Base Study in Acute Coronary Syndrome Patients
The AstraZeneca-sponsored clinical trial using a Sicilian administrative data base in patients with acute coronary syndrome and acute myocar…
-
EMA withdrawal · 2012-07-26EMA Withdrawn: Clopidogrel Hexal (clopidogrel) — Acino Pharma GmbH
Clopidogrel Hexal (clopidogrel) has been withdrawn from the market by Acino Pharma GmbH.
-
CLINICAL_TRIALS withdrawal · 2012-02-22Clinical Trial Update: Telephone Intervention in Patients With Acute Coronary Syndrome (ACS) and Diabetes [NA]
A clinical trial evaluating a telephone intervention for patients with acute coronary syndrome and type 2 diabetes was terminated.